Search

Displaying results 1731 - 1740 of 8517 in total
  1. Drug

    Alcaftadine

    go.drugbank.com/drugs/DB06766
    Approved

    This drug was approved in July 2010.

  2. Drug

    Elagolix

    go.drugbank.com/drugs/DB11979
    ApprovedInvestigational

    As of 24 July 2018, however, the U.S. … Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review [F815], this expedited new approval gives healthcare professionals another valuable option for treating the potentially

  3. Drug

    Eprosartan

    go.drugbank.com/drugs/DB00876
    ApprovedInvestigational

    Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation oc...

  4. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    Linvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma … This mechanism results in the targeted release of cytokines such as IL-2, IL-6, and IFN-gamma, promoting the selective lysis of BCMA-expressing cells and offering a novel immunotherapeutic approach for

  5. Drug

    Proxibarbal

    go.drugbank.com/drugs/DB13253
    Approved

    Proxibarbal was approved in France but was withdrawn from the market due to the risk of inducing immunoallergic thrombocytopenia [L5476]. … Proxibarbal is a derivative of barbiturates, which has been used to treat migraines.

  6. Drug

    Tilbroquinol

    go.drugbank.com/drugs/DB13222
    Approved

    Tilbroquinol was approved in France, Morocco, and Saudi Arabia but it has been withdrawn in France and Saudi Arabia markets mainly due to its hepatotoxicity risk outweighing the drug benefit [L5467]. … In Morocco, the drug has been limited to use in the treatment of intestinal amoebiasis.

  7. Drug

    Methscopolamine bromide

    go.drugbank.com/drugs/DB00462
    Approved

    A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.

  8. Drug

    Aprepitant

    go.drugbank.com/drugs/DB00673
    ApprovedInvestigational

    Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).

  9. Drug

    Macitentan

    go.drugbank.com/drugs/DB08932
    ApprovedInvestigational

    A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024. … [L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity.

  10. Drug

    Tolcapone

    go.drugbank.com/drugs/DB00323
    ApprovedInvestigationalWithdrawn

    It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound.